The increased risk of hypoglycemia following RYGB may be attributed to several factors, including increased glycemic variability, altered glucose metabolism, increased insulin sensitivity, and enhanced glucagon-like peptide-1 (GLP-1) response which are particularly evident at 1 and 2 year time points [15, 16]. This evidence concerns the gene INS and Hypoglycemia.